\BOOKMARK [1][-]{section.1}{Summary of Research}{}% 1
\BOOKMARK [2][-]{subsection.1.1}{Background on Pharmacovigilance, AERS and Social Media}{section.1}% 2
\BOOKMARK [2][-]{subsection.1.2}{Experimental Data}{section.1}% 3
\BOOKMARK [3][-]{subsubsection.1.2.1}{Tokenization Study of Data}{subsection.1.2}% 4
\BOOKMARK [3][-]{subsubsection.1.2.2}{A Vocabulary for Experimentation}{subsection.1.2}% 5
\BOOKMARK [2][-]{subsection.1.3}{Language Identification for Messages}{section.1}% 6
\BOOKMARK [2][-]{subsection.1.4}{Experimentation and Results}{section.1}% 7
\BOOKMARK [3][-]{subsubsection.1.4.1}{Class Separability Confirmed via Kullback-Leibler Divergence}{subsection.1.4}% 8
\BOOKMARK [3][-]{subsubsection.1.4.2}{Named Entity Recognition in Messages}{subsection.1.4}% 9
\BOOKMARK [3][-]{subsubsection.1.4.3}{Handling Multiple Drug Names}{subsection.1.4}% 10
\BOOKMARK [3][-]{subsubsection.1.4.4}{Sentiment Feature}{subsection.1.4}% 11
\BOOKMARK [3][-]{subsubsection.1.4.5}{Feature Selection, Training and Test Data Size}{subsection.1.4}% 12
\BOOKMARK [3][-]{subsubsection.1.4.6}{Classification Experiments and Results}{subsection.1.4}% 13
\BOOKMARK [2][-]{subsection.1.5}{Sentiment, Named Entities and Classification}{section.1}% 14
\BOOKMARK [2][-]{subsection.1.6}{Support Vector Machines}{section.1}% 15
\BOOKMARK [2][-]{subsection.1.7}{Naive Bayes Classification}{section.1}% 16
\BOOKMARK [2][-]{subsection.1.8}{Feature Selection}{section.1}% 17
\BOOKMARK [2][-]{subsection.1.9}{Evaluation Metrics Used}{section.1}% 18
\BOOKMARK [1][-]{section.2}{Discussion of Contributions}{}% 19
\BOOKMARK [1][-]{section.3}{Research Critique}{}% 20
\BOOKMARK [1][-]{section.4}{Literature Review}{}% 21
\BOOKMARK [1][-]{section.5}{Application Areas}{}% 22
\BOOKMARK [1][-]{section.6}{Concluding Remarks}{}% 23
\BOOKMARK [1][-]{section.7}{Paper Criteria \(Grading\)}{}% 24
